

18 February 2026

## Amara Raja Energy & Mobility

*BESS announcement augurs well despite soft show; upgrade to BUY*

Amara Raja Energy & Mobility reported standalone EBITDA of Rs4.13bn (down 10% y/y) vs. lower than our estimate of Rs3.94bn due to lower-than-expected revenues and gross margin. As the outlook for automotive and industrial demand is bright in lead acid batteries, the company is expected to gain share, going forward. Further, margin is expected to expand with new tubular battery and recycling plant. It also plans to set up a lithium-ion cell manufacturing plant, which is expected to commence operations from end-FY27. Further, one 5GWh BESS solutions plant has been approved with a revenue potential up to Rs28bn by FY30e. We introduce estimate for FY28e with 8/12/14% revenue/EBITDA/PAT growth. We turn positive with the BESS announcement. At CMP, the stock is reasonably valued at 15/13x on FY27/28e. We upgrade our rating on the stock to BUY with a TP of Rs1,050 (from Rs1,125 earlier), valuing it at 12x FY28e parent EPS (vs. 12x FY27e EPS previously), ARACT NPV (new lithium energy unit) at Rs210/share and BESS at Rs73/share.

**Lower-than-Estimated Performance from Key Metrics:** Standalone revenue grew 6% y/y to Rs33.51bn (below our estimate of Rs34.39bn). Further, EBITDA fell 10% to Rs3.75bn (lower than our estimate of Rs4.13bn) due to lower-than-expected revenue and gross margin (down 140bps y/y to 31.8%). Notably, the tax rate was lower at 22.2% in Q3FY26 vs. 35.5% in Q3FY25. Accordingly, APAT fell 3% y/y to Rs1.95bn (lower than our estimate of Rs2.06bn, mainly due to lower operating profit).

**Outlook and Valuation:** We expect parent's revenue/EBITDA to clock 9/18% CAGR over FY26-28e. Further, on account of higher input/opex cost and lower revenue/other income, we lower our EPS estimate by 19-29% for FY26/27e. We upgrade our rating on the stock to BUY with a revised TP of Rs1,050 (from Rs1,125 earlier), valuing it at 12x FY28e parent EPS (vs. 12x FY27e EPS previously); (a) the parent at 12x FY28e EPS (vs. 12x FY27e EPS previously); (b) ARACT NPV (new lithium energy unit) at Rs210/share; and (c) BESS at Rs73/share. We see ARACT's revenue/PAT at Rs43.2/2.16bn by FY31 and assign 25x multiple on discounted PAT. We see BESS's revenue/PAT at Rs22.4bn/672m by FY30 and assign 25x valuation multiple on discounted PAT. **Key Risks:** (a) Weaker growth in lead batteries; (b) lower orders for lithium-ion cell/BESS plant; and (c) adverse commodity prices.

Key Financials (Y/E Mar) - P	FY24	FY25	FY26e	FY27e	FY28e
Sales (Rs m)	1,12,603	1,24,049	1,33,441	1,45,739	1,58,038
Net profit (Rs m)	9,059	8,528	7,599	10,245	11,695
EPS (Rs)	49.5	46.6	41.5	56.0	63.9
P/E (x)	17.1	18.1	20.3	15.1	13.2
EV / EBITDA (x)	9.3	9.4	10.1	8.1	7.2
P/BV (x)	2.3	2.1	1.9	1.7	1.5
RoE (%)	14.2	12.1	9.8	11.9	12.2
RoCE (%)	13.2	11.9	9.3	11.0	11.5
Dividend yield (%)	0.6	0.6	0.5	0.7	0.8
Net debt / equity (x)	-0.0	-0.0	0.0	0.0	0.0

Source: Company, Anand Rathi Research

Rating: **BUY**

Target Price: Rs.1,050


Share Price: Rs.844

Key Data	AREN IN / AMAR.BO
52-week high / low	Rs1109 / 810
Sensex / Nifty	83451 / 25725
Market cap	Rs161bn
Shares outstanding	183m

Shareholding Pattern (%)	Dec'25	Sep'25	Jun'25
Promoters	32.9	32.9	32.9
- of which, Pledged	-	-	-
Free float	67.1	67.1	67.1
- Foreign institutions	17.4	18.0	19.4
- Domestic institutions	17.1	16.2	14.0
- Public	32.7	32.9	33.8

Estimates Revision (%)	FY26e	FY27e
Sales	-3.1	-3.5
EBITDA	-17.5	-11.3
EPS	-28.7	-19.4

### Relative Price Performance



Source: Bloomberg

### Mumuksh Mandlesha

Research Analyst  
+9122 6915 7418  
mumukshmandlesha@rathi.com

### Shagun Beria

Research Associate  
shagunberia@rathi.com

### Dishant Jain

Research Associate  
dishantjain@rathi.com

Anand Rathi Share and Stock Brokers Limited (hereinafter "ARSSBL") is a full-service brokerage and equities-research firm and the views expressed therein are solely of ARSSBL and not of the companies which have been covered in the Research Report. This report is intended for the sole use of the Recipient. Disclosures and analyst certifications are present in the Appendix.

## Quick Glance – Financials and Valuations (Standalone)

**Fig 1 – Income Statement (Rs m)**


Y/E Mar	FY24	FY25	FY26e	FY27e	FY28e
Net revenues	1,12,603	1,24,049	1,33,441	1,45,739	1,58,038
<i>Growth (%)</i>	8.4	10.2	7.6	9.2	8.4
Raw material	75,341	84,071	91,274	97,718	1,05,648
Employee & other expenses	21,048	23,687	26,658	28,787	30,940
<b>EBITDA</b>	<b>16,214</b>	<b>16,291</b>	<b>15,509</b>	<b>19,234</b>	<b>21,450</b>
<i>EBITDA margins (%)</i>	14.4	13.1	11.6	13.2	13.6
- Depreciation	4,787	4,921	5,514	5,973	6,306
Other income	1,015	933	845	878	913
Interest expenses	332	422	358	388	358
PBT	12,110	10,770	11,262	13,751	15,699
<i>Effective tax rates (%)</i>	26%	30%	26%	26%	26%
Adj. income	9,059	8,528	7,599	10,245	11,695
Extraordinary items	-	-1,111	780	-	-
Net income	9,059	7,418	8,379	10,245	11,695
WANS	183	183	183	183	183
FDEPS (Rs)	49.5	46.6	41.5	56.0	63.9
<i>Growth (%)</i>	8.6	-5.9	-10.9	34.8	14.2

**Fig 3 – Cash-flow Statement (Rs m)**

Y/E Mar	FY24	FY25	FY26e	FY27e	FY28e
PBT	9,059	7,418	8,379	10,245	11,695
+ Non-cash items	4,787	4,921	5,514	5,973	6,306
Operating profit before WC chg	13,846	12,338	13,893	16,217	18,002
- Incr./ (decr.) in WC	271	-85	1,014	1,304	1,331
Others incl. taxes	571	-1,107	-	-	-
<b>Operating cash-flow</b>	<b>13,004</b>	<b>13,530</b>	<b>12,879</b>	<b>14,913</b>	<b>16,670</b>
- Capex (tangible + intangible)	4,401	7,440	7,000	4,000	4,000
<b>Free cash-flow</b>	<b>8,603</b>	<b>6,090</b>	<b>5,879</b>	<b>10,913</b>	<b>12,670</b>
- Dividend (incl. buyback & taxes)	1,367	1,904	760	1,024	1,170
+ Equity raised	12	-	-	-	-
+ Debt raised	-577	902	3,000	-1,000	-1,000
- Financial investments	5,317	5,157	8,500	9,000	10,000
- Misc. items (CFI + CFF)	1,307	(677)	-	-	-
Net cash-flow	46	608	-381	-111	501

Source: Company, Anand Rathi Research

**Fig 5 – Price Movement**



Source: Bloomberg

**Fig 2 – Balance Sheet (Rs m)**


Y/E Mar	FY24	FY25	FY26e	FY27e	FY28e
Share capital	183	183	183	183	183
Net worth	67,687	73,783	81,402	90,622	1,01,148
Debt (incl. Pref)	533	1,445	4,445	3,445	2,445
Minority interest	-	-	-	-	-
Deferred tax liability / (Asset)	885	732	732	732	732
<b>Capital employed</b>	<b>69,105</b>	<b>75,960</b>	<b>86,579</b>	<b>94,799</b>	<b>1,04,325</b>
Net tangible assets	35,503	34,747	36,233	34,260	31,954
Net Intangible assets	-	-	-	-	-
CWIP (tang and intangible)	3,217	8,441	8,441	8,441	8,441
Investments (strategic)	12,142	19,355	27,855	36,855	46,855
Investments (financial)	2,650	625	625	625	625
Current assets (excl. cash)	33,788	35,110	37,849	41,366	44,919
Cash	1,045	1,653	1,272	1,161	1,662
Current liabilities	19,238	23,970	25,695	27,908	30,130
Working capital	14,549	11,140	12,154	13,458	14,789
<b>Capital deployed</b>	<b>69,105</b>	<b>75,960</b>	<b>86,579</b>	<b>94,799</b>	<b>1,04,325</b>

**Fig 4 – Ratio Analysis**

Y/E Mar	FY24	FY25	FY26e	FY27e	FY28e
P/E (x)	17.1	18.1	20.3	15.1	13.2
EV / EBITDA (x)	9.3	9.4	10.1	8.1	7.2
EV / Sales (x)	1.3	1.2	1.2	1.1	1.0
P/B (x)	2.3	2.1	1.9	1.7	1.5
RoE (%)	14.2	12.1	9.8	11.9	12.2
RoCE (%) - after tax	13.2	11.9	9.3	11.0	11.5
RoIC (%) - after tax	15.1	13.9	12.7	16.6	19.2
DPS (Rs)	5.1	5.2	4.2	5.6	6.4
Dividend yield (%)	0.6	0.6	0.5	0.7	0.8
Dividend payout (%)	10	13	9	10	10
Net debt / equity (x)	-0.0	-0.0	0.0	0.0	0.0
Receivables (days)	33	34	34	34	34
Inventory (days)	59	60	60	60	60
Payables (days)	53	60	60	60	60
CFO : PAT (%)	144	159	169	146	143

Source: Company, Anand Rathi Research

**Fig 6 – Standalone Revenue (%) by Segment - FY25**



Source: Company

## Result Highlights

**Fig 7 – Quarterly Performance (Standalone)**

(Rs M)	Q3FY25	Q4FY25	Q1FY26	Q2FY26	Q3FY26	Y/Y (%)	Q/Q (%)	YTD FY26	YTD FY25	Y/Y (%)
<b>Revenue</b>	<b>31,640</b>	<b>29,739</b>	<b>33,499</b>	<b>33,882</b>	<b>33,508</b>	<b>5.9</b>	<b>(1.1)</b>	<b>1,00,889</b>	<b>94,310</b>	<b>7.0</b>
<b>Expenditure</b>	<b>27,482</b>	<b>26,316</b>	<b>29,633</b>	<b>29,822</b>	<b>29,763</b>	<b>8.3</b>	<b>(0.2)</b>	<b>89,218</b>	<b>81,442</b>	<b>9.5</b>
as % of sales	86.9	88.5	88.5	88.0	88.8			88.4	86.4	
Consumption of RM	21,164	20,132	23,629	22,776	22,868	8.1	0.4	69,272	63,939	8.3
as % of sales	66.9	67.7	70.5	67.2	68.2			68.7	67.8	
Employee cost	1,912	1,801	1,976	2,231	2,046	7.0	(8.3)	6,253	5,667	10.3
as % of sales	6.0	6.1	5.9	6.6	6.1			6.2	6.0	
Other expenditure	4,406	4,383	4,028	4,816	4,849	10.1	0.7	13,693	11,836	15.7
as % of sales	13.9	14.7	12.0	14.2	14.5			13.6	12.6	
<b>EBITDA</b>	<b>4,158</b>	<b>3,422</b>	<b>3,867</b>	<b>4,059</b>	<b>3,745</b>	<b>(9.9)</b>	<b>(7.7)</b>	<b>11,671</b>	<b>12,869</b>	<b>(9.3)</b>
<b>EBITDA margins (%)</b>	<b>13.1</b>	<b>11.5</b>	<b>11.5</b>	<b>12.0</b>	<b>11.2</b>			<b>11.6</b>	<b>13.6</b>	
Depreciation	1,233	1,284	1,292	1,380	1,409	14.2	2.1	4,081	3,637	12.2
EBIT	2,925	2,138	2,574	2,679	2,336	(20.1)	(12.8)	7,590	9,232	(17.8)
Other income	293	200	139	241	263	(9.9)	9.4	644	733	(12.2)
Interest	107	95	104	83	87	(18.4)	5.2	273	328	(16.6)
PBT	3,111	2,244	2,610	2,838	2,513	(19.2)	(11.4)	7,961	9,637	(17.4)
Total tax	1,103	576	670	1,032	558	(49.4)	(45.9)	2,259	2,777	(18.6)
<b>Adjusted PAT</b>	<b>2,008</b>	<b>1,668</b>	<b>1,940</b>	<b>1,806</b>	<b>1,955</b>	<b>(2.6)</b>	<b>8.2</b>	<b>5,701</b>	<b>6,860</b>	<b>(16.9)</b>
Extraordinary items Loss/(Gain)	-1,111	0	0	-1,218	438			-780	-1,111	
Reported PAT	3,118	1,668	1,940	3,024	1,517	(51.4)	(49.8)	6,481	7,971	(18.7)
<b>Adjusted EPS</b>	<b>11.0</b>	<b>9.1</b>	<b>10.6</b>	<b>9.9</b>	<b>10.7</b>	<b>(2.6)</b>	<b>8.2</b>	<b>31.2</b>	<b>37.5</b>	<b>(16.9)</b>
<b>Margins (%)</b>						<b>(bps)</b>	<b>(bps)</b>			<b>(bps)</b>
Gross	33.1	32.3	29.5	32.8	31.8	(136)	(103)	31.3	32.2	(87)
EBITDA	13.1	11.5	11.5	12.0	11.2	(197)	(80)	11.6	13.6	(208)
EBIT	9.2	7.2	7.7	7.9	7.0	(227)	(94)	7.5	9.8	(227)
PAT	6.3	5.6	5.8	5.3	5.8	(51)	50	5.7	7.3	(162)
Effective tax rate	35.5	25.7	25.7	36.4	22.2	(1,326)	(1,415)	28.4	28.8	(43)

Source: Company

## Earnings Concall – Key Highlights

### Lead Acid Biz

- **Quarterly Volume:** Domestic 4W volume rose 7% y/y (OEM: 25% and Aftermarket: 3%). 2W volume rose by 1% y/y, due to a high base (15-17% growth in Q3FY25) and a platform-specific OEM temporary shutdown. Other segments (tubular and home UPS) grew 10%, aided by higher in-house tubular production. Industrial volume (ex-telecom) rose 2% and UPS increased 5%, while telecom fell 45% (<5% of revenue). Export down 15% y/y due to tariff-related and competitive pressure (Middle East and APAC markets). Telecom segment market share stood at ~55%, combined across lead-acid and lithium battery offerings.
- **Quarterly Margin:** Sequential contraction in gross margin is attributed to higher RM cost (tin/antimony alloys, sulphuric acid and lead) and OEM-mix. EBITDA margin contracted q/q due to lower gross margin and higher warranty/EPR provisioning, partly offset by ~60bps uplift from recycling plant. The management expects a normal tubular season could support margin in Q4 FY26, while it targets ~13-14% EBITDA margin in the medium-term, subject to cost normalisation and mix recovery.
- **Price Hike:** The company hiked the prices by ~2% in Jan-26 to mitigate the commodity inflation. RM cost pass-through to OEMs is limited to lead, while cost increases for other RMs are not pass through.
- **Capacity:** Recycling plant refining is operational and battery breaking to start by Q1 FY27.
- **Capex:** FY26 guided at ~Rs7-8bn (including tubular plant reinstatement, partly insurance-funded), normalising to ~Rs3-4bn in FY27e.

### Lithium Battery Biz

- **Quarterly Snippets:** Revenue more than doubled to Rs2.36bn. It supplied ~250MWh of telecom packs, driving ~80% stationary capacity utilisation. Total telecom demand opportunity is currently <3GWh.
- **BESS Solutions Plant:** Capex of ~Rs2.8bn is approved for 5GWh BESS solutions plant, which is expected to be operational by Q4 FY27. It expects 25-30GWh market opportunity by FY31e across grid and C&I segment from <1GWh currently. Initially, BESS will use 314Ah LFP cells with imported content and gradual localisation. **Revenue potential of plant is seen at Rs27-28bn** (9-10x asset turns due to solution architecture – battery packs, and inverter DC blocks etc.) with gradual ramp-up, as requirement builds (but tenders are evolving quickly). It expects 15% market share with 5GWh capacity. Whilst operating margin is expected to be low, RoCE should be good due to higher asset turns.
- **Investment and Capex:** The company infused ~Rs2bn into ARACT in Q3 FY26, taking total investment to ~Rs14bn. It incurred ~Rs3bn capex YTD.

## Outlook and Valuation

### Lithium Cell Batteries

- AMRJ plans to set up a lithium-ion cell manufacturing plant, which is to be gradually commissioned from FY27e.
- It has developed NMC technology with Highstar, while LFP technologies are being developed with Gotion Inobat.
- E positive labs, customer qualification (60MWh/year) and NMC cell (2GWh) plants are being constructed at Rs20bn capex and would be ready by H2 FY27.
- The LFP cell plant could be of 4-5 GWh with two cell types and would be ready by CY27/28e with Rs20-25bn capex. Average realisation is expected at \$80-90/kWh.
- Larger customer wins and sustainable profitability are the key monitorable ahead.

### Battery Packs, Chargers

- Battery packs are supplied to 3W OEMs (Piaggio, M&M) and telecoms (BSNL, Indus Towers, Airtel, Vi). Chargers are supplied to 3W OEMs (M&M, Piaggio).
- The company is preparing for 2W and certain high-voltage applications, having entered a technology agreement. Battery pack capacity at 2.5GW/h (including 1 GWh for telecoms).
- Q3 revenue has already jumped to Rs2.36bn and supplied ~250 MWh of telecom packs, driving ~80% of stationary capacity utilization.

### Lead Batteries

- The outlook for automotive and industrial demand is bright. Volume growth would be in high-single digits.
- We expect a 9% revenue CAGR over FY26-28. Margins would improve, led by better nett pricing and new tubular/recycling plant.

**Valuation:** We expect parent's revenue/EBITDA to clock 9/18% CAGR over FY26-28e. We recommend BUY with a revised TP of Rs1,050, valuing it at 12x FY28e parent EPS, valuing (a) parent at 12x FY28e EPS; (b) ARACT NPV (new lithium energy unit) at Rs210/share; and (c) BESS at Rs73/share. We see ARACT's revenue/PAT at Rs43.2/2.16bn by FY31 and assign 25x multiple on discounted PAT. We see BESS's revenue/PAT at Rs22.4bn/672m by FY30 and assign 25x valuation multiple on discounted PAT.

**Fig 8 – Change in Estimates – Standalone**

Y/E Mar (Rs m)	Old Estimates		New Estimates		Change (%)		Introducing
	FY26e	FY27e	FY26e	FY27e	FY26	FY27	FY28e
Revenue	1,37,734	1,50,993	1,33,441	1,45,739	-3.1	-3.5	1,58,038
EBITDA	18,807	21,675	15,509	19,234	-17.5	-11.3	21,450
% of revenue	13.7	14.4	11.6	13.2			13.6
Adj. PAT	10,652	12,709	7,599	10,245	-28.7	-19.4	11,695
EPS (Rs)	58.2	69.4	41.5	56.0	-28.7	-19.4	63.9

Source: Anand Rath Research

**Fig 9 – Key Assumptions – Standalone**

(Rs M)	FY23	FY24	FY25	FY26e	FY27e	FY28e	CAGR % FY26-28e
Automotive (2Ws, 4Ws)	67,006	74,498	89,665	1,00,820	1,12,092	1,23,213	11
Growth (%)	20	11	20	12	11	10	
-OEM	11,398	12,253	14,164	17,580	19,545	21,263	10
Growth (%)	24	8	16	24	11	9	
-Aftermarket	55,608	62,245	75,502	83,241	92,547	1,01,950	11
Growth (%)	19	12	21	10	11	10	
Industrial	31,376	34,700	30,347	28,013	28,578	29,249	2
Growth (%)	11	11	(13)	(8)	2	2	
Others	3,021	3,405	4,037	4,608	5,069	5,576	10
Growth (%)	14	13	19	14	10	10	
<b>Total revenue</b>	<b>1,01,403</b>	<b>1,12,603</b>	<b>1,24,049</b>	<b>1,33,441</b>	<b>1,45,739</b>	<b>1,58,038</b>	<b>9</b>
Growth (%)	17	11	10	8	9	8	

Source: Anand Rathi Research

**Fig 10 – 1-Year Forward P/E (Median 20x) – Attractive Valuation - Below Median**

Source: Company, Anand Rathi Research

**Key Risks**

- Weaker growth in lead batteries.
- Lower orders for lithium-ion cell/BESS plant.
- Adverse commodity prices.


## Appendix

### Analyst Certification

The views expressed in this Research Report accurately reflect the personal views of the analyst(s) about the subject securities or issuers and no part of the compensation of the research analyst(s) was, is, or will be directly or indirectly related to the specific recommendations or views expressed by the research analyst(s) in this report. The research analysts are bound by stringent internal regulations and also legal and statutory requirements of the Securities and Exchange Board of India (hereinafter "SEBI") and the analysts' compensation are completely delinked from all the other companies and/or entities of Anand Rathi, and have no bearing whatsoever on any recommendation that they have given in the Research Report.

### Important Disclosures on subject companies

#### Rating and Target Price History (as of 13 February 2026)



### Anand Rathi Ratings Definitions

Analysts' ratings and the corresponding expected returns take into account our definitions of Large Caps, Mid Caps & Small Caps as described in the Ratings Table below:

#### Ratings Guide (12 months)

	Buy	Hold	Sell
Large Caps (Top 100 companies)	>15%	0-15%	<0%
Mid Caps (101st-250th company)	>20%	0-20%	<0%
Small Caps (251st company onwards)	>25%	0-25%	<0%

### Research Disclaimer and Disclosure inter-alia as required under Securities and Exchange Board of India (Research Analysts) Regulations, 2014

Anand Rathi Share and Stock Brokers Ltd. (hereinafter refer as ARSSBL) (Research Entity, SEBI Regn No. INH000000834, Date of Regn. 29/06/2015, BSE Enlistment Number – 5048 date of Regn 25 July 2024) is a subsidiary of the Anand Rathi Financial Services Ltd. ARSSBL is a corporate trading and clearing member of Bombay Stock Exchange Ltd (BSE), National Stock Exchange of India Ltd. (NSEIL), Multi Commodity Exchange of India Limited (MCX), National Commodity & Derivatives Exchange Limited (NCDEX), and also depository participant with National Securities Depository Ltd (NSDL) and Central Depository Services Ltd. (CDSL), ARSSBL is engaged into the business of Stock Broking, Depository Participant, Mutual Fund distributor.

The research analysts, strategists, or research associates principally responsible for the preparation of Anand Rathi research have received compensation based upon various factors, including quality of research, investor client feedback, stock picking, competitive factors and firm revenues.

**General Disclaimer:** This Research Report (hereinafter called "Report") is meant solely for use by the recipient and is not for circulation. This Report does not constitute a personal recommendation or take into account the particular investment objectives, financial situations, or needs of individual clients. The recommendations, if any, made herein are expression of views and/or opinions and should not be deemed or construed to be neither advice for the purpose of purchase or sale of any security, derivatives or any other security through ARSSBL nor any solicitation or offering of any investment/trading opportunity on behalf of the issuer(s) of the respective security (ies) referred to herein. These information / opinions / views are not meant to serve as a professional investment guide for the readers. No action is solicited based upon the information provided herein. Recipients of this Report should rely on information/data arising out of their own investigations. Readers are advised to seek independent professional advice and arrive at an informed trading/investment decision before executing any trades or making any investments. This Report has been prepared on the basis of publicly available information, internally developed data and other sources believed by ARSSBL to be reliable. ARSSBL or its directors, employees, affiliates or representatives do not assume any responsibility for, or warrant the accuracy, completeness, adequacy and reliability of such information / opinions / views. While due care has been taken to ensure that the disclosures and opinions given are fair and reasonable, none of the directors, employees, affiliates or representatives of ARSSBL shall be liable for any direct, indirect, special, incidental, consequential, punitive or exemplary damages, including lost profits arising in any way whatsoever from the information / opinions / views contained in this Report. The price and value of the investments referred to in this Report and the income from them may go down as well as up, and investors may realize losses on any investments. Past performance is not a guide for future performance. ARSSBL does not provide tax advice to its clients, and all investors are strongly advised to consult with their tax advisers regarding taxation aspects of any potential investment.

Opinions expressed are our current opinions as of the date appearing on this Research only. We do not undertake to advise you as to any change of our views expressed in this Report. Research Report may differ between ARSSBL's RAs and/ or ARSSBL's associate companies on account of differences in research methodology, personal judgment and difference in time horizons for which recommendations are made. User should keep this risk in mind and not hold ARSSBL, its employees and associates responsible for any losses, damages of any type whatsoever.

ARSSBL and its associates or employees may; (a) from time to time, have long or short positions in, and buy or sell the investments in/ security of company (ies) mentioned herein or (b) be engaged in any other transaction involving such investments/ securities of company (ies) discussed herein or act as advisor or lender / borrower to such company (ies) these and other activities of ARSSBL and its associates or employees may not be construed as potential conflict of interest with respect to any recommendation and related information and opinions. Without limiting any of the foregoing, in no event shall ARSSBL and its associates or employees or any third party involved in, or related to computing or compiling the information have any liability for any damages of any kind.

Details of Associates of ARSSBL and Brief History of Disciplinary action by regulatory authorities & its associates are available on our website i.e. [www.rathionline.com](http://www.rathionline.com)

**Disclaimers in respect of jurisdiction:** This report is not directed to, or intended for distribution to or use by, any person or entity who is a citizen or resident of or located in any locality, state, country or other jurisdiction where such distribution, publication, availability or use would be contrary to law or regulation or which would subject ARSSBL to any registration or licensing requirement within such jurisdiction(s). No action has been or will be taken by ARSSBL in any jurisdiction (other than India), where any action for such purpose(s) is required. Accordingly, this Report shall not be possessed, circulated and/or distributed in any such country or jurisdiction unless such action is in compliance with all applicable laws and regulations of such country or jurisdiction. ARSSBL requires such recipient to inform himself about and to observe any restrictions at his own expense, without any liability to ARSSBL. Any dispute arising out of this Report shall be subject to the exclusive jurisdiction of the Courts in India.

#### Statements on ownership and material conflicts of interest, compensation - ARSSBL and Associates

##### Answers to the Best of the knowledge and belief of ARSSBL/ its Associates/ Research Analyst who is preparing this report

Research analyst or research entity or his associate or his relative has any financial interest in the subject company and the nature of such financial interest.	No
ARSSBL/its Associates/ Research Analyst/ his Relative have actual/beneficial ownership of one per cent or more securities of the subject company, at the end of the month immediately preceding the date of publication of the research report?	No
ARSSBL/its Associates/ Research Analyst/ his Relative have actual/beneficial ownership of one per cent or more securities of the subject company	No
ARSSBL/its Associates/ Research Analyst/ his Relative have any other material conflict of interest at the time of publication of the research report?	No
ARSSBL/its Associates/ Research Analyst/ his Relative have received any compensation from the subject company in the past twelve months	No
ARSSBL/its Associates/ Research Analyst/ his Relative have managed or co-managed public offering of securities for the subject company in the past twelve months	No
ARSSBL/its Associates/ Research Analyst/ his Relative have received any compensation for investment banking or merchant banking or brokerage services from the subject company in the past twelve months	No
ARSSBL/its Associates/ Research Analyst/ his Relative have received any compensation for products or services other than investment banking or merchant banking or brokerage services from the subject company in the past twelve months	No
ARSSBL/its Associates/ Research Analyst/ his Relative have received any compensation or other benefits from the subject company or third party in connection with the research report	No
ARSSBL/its Associates/ Research Analyst/ his Relative have served as an officer, director or employee of the subject company.	No
ARSSBL/its Associates/ Research Analyst/ his Relative has been engaged in market making activity for the subject company.	No

#### NOTICE TO US INVESTORS:

This research report is the product of Anand Rathi Share and Stock Brokers Limited, which is the employer of the research analyst(s) who has prepared the research report. The research analyst(s) preparing the research report is/are resident outside the United States (U.S.) and are not associated person(s) of any U.S. regulated broker-dealer and therefore the analyst(s) is/are not subject to supervision by a U.S. broker-dealer, and is/are not required to satisfy the regulatory licensing requirements of FINRA or required to otherwise comply with U.S. rules or regulations regarding, among other things, communications with a subject company, public appearances, and trading securities held by a research analyst account.

Research reports are intended for distribution only to Major U.S. Institutional Investors as defined by Rule 15a-6(b)(4) of the U.S. Securities and Exchange Act of 1934 (the Exchange Act) and interpretations thereof by the U.S. Securities and Exchange Commission (SEC) in reliance on Rule 15a-6(a)(2). If the recipient of this research report is not a Major U.S. Institutional Investor as specified above, then it should not act upon this report and return the same to the sender. Further, this report may not be copied, duplicated, and/or transmitted onward to any U.S. person which is not a Major U.S. Institutional Investor. In reliance on the exemption from registration provided by Rule 15a-6 of the Exchange Act and interpretations thereof by the SEC in order to conduct certain business with Major U.S. Institutional Investors, Anand Rathi Share and Stock Brokers Limited has entered into a Strategic Partnership and chaperoning agreement with a U.S. registered broker-dealer: Banc Trust Securities USA. Transactions in securities discussed in this research report should be affected through Banc Trust Securities USA.

1. ARSSBL or its Affiliates may or may not have been beneficial owners of the securities mentioned in this report.
2. ARSSBL or its affiliates may have or not managed or co-managed a public offering of the securities mentioned in the report in the past 12 months.
3. ARSSBL or its affiliates may have or not received compensation for investment banking services from the issuer of these securities in the past 12 months and do not expect to receive compensation for investment banking services from the issuer of these securities within the next three months.
4. However, one or more of ARSSBL or its Affiliates may, from time to time, have a long or short position in any of the securities mentioned herein and may buy or sell those securities or options thereon, either on their own account or on behalf of their clients.
5. As of the publication of this report, ARSSBL does not make a market in the subject securities.
6. ARSSBL or its Affiliates may or may not, to the extent permitted by law, act upon or use the above material or the conclusions stated above, or the research or analysis on which they are based before the material is published to recipients and from time to time, provide investment banking, investment management or other services for or solicit to seek to obtain investment banking, or other securities business from, any entity referred to in this report.

© 2026. This report is strictly confidential and is being furnished to you solely for your information. All material presented in this report, unless specifically indicated otherwise, is under copyright to ARSSBL. None of the material, its content, or any copy of such material or content, may be altered in any way, transmitted, copied or reproduced (in whole or in part) or redistributed in any form to any other party, without the prior express written permission of ARSSBL. All trademarks, service marks and logos used in this report are trademarks or service marks or registered trademarks or service marks of ARSSBL or its affiliates, unless specifically mentioned otherwise.

As of the publication of this report, ARSSBL does not make a market in the subject securities.

Registration granted by SEBI, Enlistment as RA and certification from NISM in no way guarantee performance of the intermediary or provide any assurance of returns to investors.

Additional information on recommended securities/instruments is available on request.

**Compliance officer:** Deepak Kedia, email id: [deepakkedia@rathi.com](mailto:deepakkedia@rathi.com), Contact no. +91 22 6281 7000  
**Grievance officer:** Madhu Jain, email id: [grievance@rathi.com](mailto:grievance@rathi.com), Contact no. +91 22 6281 7191

**ARSSBL registered address:** Express Zone, A Wing, 10th Floor, Western Express Highway, Diagonally Opposite Oberoi Mall, Malad (E), Mumbai – 400097.  
Tel No: +91 22 6281 7000 | Fax No: +91 22 4001 3770 | CIN: U67120MH1991PLC064106.